MAPT and Alzheimer disease: A recent meta-analysis indicated that blood levels of Aβ42/40 ratio and Tau-pT181 protein strongly predicted the Aβ-PET status in patients [45] and that blood Aβ42/40 ratio was even recommended as a cost-effective marker for early AD pathological screening [46].